Sagimet Biosciences (SGMT) Stock Price, News & Analysis

Company Overview

Sagimet Biosciences, Inc. is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel small molecule therapies for metabolic diseases, with an initial emphasis on nonalcoholic steatohepatitis (NASH). The company’s lead candidate, SGMT-05, is an orally administered agent in development to reduce liver fat accumulation and fibrosis through a multifaceted mechanism targeting key pathways implicated in NASH. In parallel, Sagimet maintains a preclinical pipeline that includes compounds aimed at addressing dyslipidemia and cardiometabolic risk factors, leveraging proprietary medicinal chemistry platforms to optimize pharmacokinetic and safety profiles.

Founded in 2014, Sagimet is headquartered in the United States and has established research collaborations and partnerships across North America, Europe and Asia. The company operates state‐of‐the‐art laboratory facilities and works closely with contract research organizations and academic institutions to accelerate its translational and clinical research programs. Over the years, Sagimet has secured non‐dilutive funding and strategic alliances to support its scientific agenda and expand its global footprint in metabolic disease research.

The Sagimet leadership team is composed of seasoned executives with deep experience in biotechnology, pharmaceutical development and regulatory affairs. Led by a chief executive officer with over two decades of drug development expertise, the senior management team guides the company’s strategy from early discovery through clinical proof of concept. Sagimet’s board of directors includes industry veterans who have held leadership roles at major biopharmaceutical firms, providing governance and strategic insight to drive the company’s mission.

With a mission to address the significant unmet medical need in NASH and related metabolic disorders, Sagimet Biosciences is positioned to advance its innovative small molecule pipeline through clinical development and regulatory milestones. By combining scientific rigor with strategic partnerships, the company aims to deliver safe and effective therapies that improve patient outcomes and set new standards in metabolic disease treatment.

Key Stats

• Today's Range: $9.15 to $9.74
• 50-Day Range: $3.10 to $9.91
• 52-Week Range: $1.73 to $10.43
• Volume: 487,598 shs
• Average Volume: 1.09 million shs
• Market Capitalization: $288.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $26.60
• Consensus Rating: Buy

Sagimet Biosciences Stock Analysis - MarketRank™

Sagimet Biosciences scored higher than 47% of companies evaluated by MarketBeat, and ranked 613th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Sagimet Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Sagimet Biosciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Sagimet Biosciences are expected to decrease in the coming year, from ($1.60) to ($4.03) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Sagimet Biosciences is -5.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sagimet Biosciences is -5.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Sagimet Biosciences has a P/B Ratio of 1.85. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

15.27% of the float of Sagimet Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Sagimet Biosciences has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sagimet Biosciences has recently decreased by 4.72%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sagimet Biosciences does not currently pay a dividend.

Dividend Growth

Sagimet Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

15.27% of the float of Sagimet Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Sagimet Biosciences has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sagimet Biosciences has recently decreased by 4.72%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: N/A

News Sentiment

Sagimet Biosciences has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Sagimet Biosciences this week, compared to 2 articles on an average week.

Search Interest

Only 12 people have searched for SGMT on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Sagimet Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sagimet Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.70% of the stock of Sagimet Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

87.86% of the stock of Sagimet Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SGMT Stock Analysis - Frequently Asked Questions

How have SGMT shares performed this year?

Sagimet Biosciences' stock was trading at $4.50 at the start of the year. Since then, SGMT stock has increased by 109.1% and is now trading at $9.41.

How were Sagimet Biosciences' earnings last quarter?

Sagimet Biosciences Inc. (NASDAQ:SGMT) announced its quarterly earnings results on Thursday, May, 8th. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.79) by $0.23.

When did Sagimet Biosciences IPO?

Sagimet Biosciences (SGMT) raised $85 million in an initial public offering on Friday, July 14th 2023. The company issued 5,312,500 shares at $16.00 per share.

Who are Sagimet Biosciences' major shareholders?

Top institutional shareholders of Sagimet Biosciences include ORG Wealth Partners LLC (0.06%). Insiders that own company stock include Enterprise Associates 13 L New, David Happel, Elizabeth Rozek, George Kemble, Eduardo Bruno Martins and Beth C Seidenberg.
View institutional ownership trends.

How do I buy shares of Sagimet Biosciences?

Shares of SGMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Sagimet Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sagimet Biosciences investors own include XPeng (XPEV), Iovance Biotherapeutics (IOVA), Taiwan Semiconductor Manufacturing (TSM), Avino Silver & Gold Mines (ASM), Tenet Healthcare (THC) and Urogen Pharma (URGN).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SGMT
• CIK: 1400118
• Web: sagimet.com
• Phone: 650-561-8600
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Sagimet Biosciences: $26.60
• High Price Target: $32.00
• Low Price Target: $12.00
• Potential Upside/Downside: +189.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.76)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$45.57 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -35.21%
• Return on Assets: -34.09%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 20.34
• Quick Ratio: 20.34

Sales & Book Value

• Annual Sales: $2 million
• Price / Sales: 141.02
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.08 per share
• Price / Book: 1.81

Miscellaneous

• Outstanding Shares: 30,670,000
• Free Float: 26,166,000
• Market Cap: $282.04 million
• Optionable: Optionable
• Beta: 3.35